$DERM Cashflow Statement | Understand Stock

$DERM

$4.96 -$0.01 (0.2%) Close

$DERM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expenses
Bad debt (recovery) expense
Gain on extinguishment of debt
Non-cash interest expense
Amortization of debt discount
Accretion of convertible preferred shares
Amortization of acquired intangible assets
Amortization of operating lease right-of-use assets
Share-based compensation
Deferred taxes
Change in fair value of derivative liability
Research and development-licenses acquired, expense
Loss on impairment of intangible assets
Changes in operating assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable
Related party expenses
Accrued expenses
Accrued expenses, related party
Accrued interest
Income tax payable
Lease liabilities
Net cash (used in) operating activities

Cash flows from investing activities
Purchase of research and development licenses
Acquired intangible assets
Net cash (used in) investing activities

Cash flows from financing activities
Proceeds from the exercise of stock options
Proceeds from Fortress note
Proceeds from issuance of common stock, ATM offering, net of issuance costs
Atm offering
Total proceeds from issuance of common stock, ATM offering, net of issuance costs
Offering costs for the issuance of common stock
IPO
Total offering costs for the issuance of common stock
Issuance of common stock under ESPP
Proceeds from term-loan
Payment of debt issuance costs
Payment of license installment note payable
Proceeds from convertible preferred shares
Payment of debt issuance costs associated with convertible preferred shares
Proceeds from line of credit
Repayment of line of credit
Repayment of EWB term-loan
Net cash provided by financing activities

Net change in cash
Cash at the beginning of the period
Cash at the end of the period
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Deferred payment for asset acquisition
Supplemental disclosure of non-cash financing and investing activities:
ROU assets obtained in exchange for lease liabilities
Unpaid debt offering cost
Unpaid initial public offering cost
Derivative warrant liability associated with convertible preferred shares
Conversion of class A preferred stock settled note to common stock
Conversion of related party payables to common stock
Conversion of placement agent warrants to common stock
Conversion of contingent payment warrants to common stock
Extinguishment of related party payable relates to deferred tax assets
Unpaid intangible assets

Comments